CJC-1295 + Ipamorelin Nasal Spray 10mg

The CJC-1295 + Ipamorelin Blend is a fixed-ratio research formulation pairing two distinct GH-axis peptides in a single lyophilized vial. The vial holds five milligrams of CJC-1295 No DAC plus five milligrams of Ipamorelin, summing to ten milligrams of total peptide content. Both compounds engage the anterior pituitary somatotroph cells where growth hormone is synthesised and released, but they bind different receptors and operate through different intracellular pathways — the rationale for combined-compound research that motivates this blend format.

CJC-1295 No DAC is a synthetic 29-residue peptide derived from the parent hGHRH(1-29) fragment with four amino-acid substitutions for protease resistance. The compound binds the growth-hormone-releasing-hormone receptor on somatotrophs, mimicking endogenous GHRH and triggering an adenylyl-cyclase / cAMP / protein-kinase-A signalling cascade. Ipamorelin is a synthetic five-residue pentapeptide that acts as a selective agonist at the growth-hormone-secretagogue receptor type 1a (GHSR-1a) — the same receptor through which the endogenous hormone ghrelin signals, triggering a phospholipase C cascade. Both pathways converge on vesicular release of growth hormone but operate independently at the receptor and second-messenger level.

The compound is supplied as a lyophilized in a 10 mL intranasal-spray bottle; reconstituted with the included 0.3% potassium sorbate solution. Reconstitution with bacteriostatic water is required before either of the two component peptides can be drawn into an insulin syringe. A single 10 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL of CJC-1295 No DAC and 2.5 mg/mL of Ipamorelin simultaneously — the matched five-milligram loadings produce a one-to-one ratio across all reconstitution volumes.

The combined GHRH-plus-GHRP research framing has produced a substantial preclinical and clinical-trial-stage literature. CJC-1295 progressed through Phase 1/2 clinical trials under ConjuChem in the mid-2000s with documented prolonged GH and IGF-1 stimulation (PMID 16352683, PMID 16822960). The 2006 Ionescu paper documented that pulsatile GH secretion persisted under continuous CJC-1295 stimulation, an unexpected finding that has shaped subsequent GH-axis research interpretation (PMID 17018654). Ipamorelin's foundational characterisation as the first selective growth hormone secretagogue is anchored by the 1998 Raun paper in the European Journal of Endocrinology (PMID 9849822). The 2014 Beck Phase 2 randomised controlled trial extended Ipamorelin's clinical-research record into postoperative-ileus indications (PMID 25331030).

Across the literature the components appear under several alternate names. CJC-1295 No DAC is also called Modified GRF(1-29) or Mod-GRF(1-29). Ipamorelin acetate carries the development designation NNC 26-0161. The 2017 Drug Testing and Analysis SAR review compiled the broader peptidic GH secretagogue class within which both compounds sit (PMID 26811125). The 1997 Thorner foundational review provides the historical context for the GHRH-plus-GHRP combined research framework (PMID 9238854).

No regulatory authority — Health Canada, the FDA, the EMA, the TGA, or any equivalent — has cleared either component compound, or the blend formulation, as a drug for human or veterinary use. Neither compound is listed as a scheduled controlled substance under the international drug-control conventions or under the major national scheduling systems. Ronin Peptides ships the blend exclusively as a research-grade reagent for benchwork. Dosing protocols, treatment regimens, and administration instructions are out of scope and not provided in any form.

The blend's two components engage two distinct G-protein-coupled receptors on the same target cell type — anterior pituitary somatotrophs — but operate through different intracellular signalling cascades. Investigators studying combined GHRH-plus-GHRP protocols often cite this dual-receptor architecture as the design rationale for blend formats over single-class stimulation.

CJC-1295 No DAC's mechanism centres on agonism at the growth-hormone-releasing-hormone receptor (GHRHR), a Gs-coupled GPCR. Receptor activation triggers an adenylyl-cyclase / cAMP / protein-kinase-A signalling cascade. The 2005 Jetté Endocrinology paper characterised the parent hGRF(1-29)-albumin bioconjugate as a GRF-receptor agonist on anterior pituitary somatotroph cells (PMID 15817669). Subsequent work documented prolonged GH and IGF-1 stimulation in Phase 1/2 clinical trials (PMID 16352683) and characterised once-daily administration profiles (PMID 16822960).

Ipamorelin's mechanism centres on selective agonism at the growth-hormone-secretagogue receptor type 1a (GHSR-1a), a Gq-coupled GPCR. Receptor activation triggers a phospholipase C cascade, intracellular calcium mobilisation, and downstream stimulation of growth hormone secretion. The 1998 Raun characterisation paper documented Ipamorelin's selectivity profile — GH release without prolactin, ACTH, cortisol, or aldosterone elevations characteristic of earlier GHRPs (PMID 9849822). The 1998 Johansen pharmacokinetic paper characterised plasma half-life and absorption kinetics (PMID 9879640).

Combined-receptor research has produced findings on dual-receptor stimulation distinct from either compound alone. Both pathways converge on vesicular GH release but operate independently at the receptor and second-messenger level — researchers studying combined protocols can compare GH pulse profiles under single-class versus dual-class stimulation. The 2006 Ionescu paper documented that pulsatile GH secretion persists even under continuous receptor stimulation, suggesting somatotroph-intrinsic pulsatile release dynamics independent of receptor-binding temporal patterns (PMID 17018654).

Comparative GHRH-and-GHRP analogue research positions the blend's two components against the broader peptidic GH-secretagogue class. The 2017 Drug Testing and Analysis SAR review compiled the structural relationships across the GHRP class including Ipamorelin and related analogues (PMID 26811125). Tesamorelin, another modified GHRH analogue, has been characterised in clinical-trial-stage research for HIV-associated lipodystrophy (PMID 20554713). The 2013 Endocrinology paper used a GHRH-receptor-targeted botulinum-neurotoxin construct to characterise pulsatile GH secretion mechanisms (PMID 23825127).

GH-axis pharmacology forms the foundational research stream for both component compounds. CJC-1295's prolonged-GH-stimulation profile, anchored by the 2006 Teichman Phase 1/2 trial paper (PMID 16352683), provides the clinical-research data point for the GHRH-analogue half of the blend. Ipamorelin's 1998 selectivity characterisation provides the corresponding GHRP-half foundation (PMID 9849822). The 1997 Thorner review compiled the broader GHRH-and-GHRP therapeutic-research framework (PMID 9238854).

Pulsatile-GH-release characterisation is a research stream with particular relevance to combined-compound investigations. The 2006 Ionescu paper documented persistent pulsatile GH secretion under continuous CJC-1295 stimulation (PMID 17018654). The 2013 Leggett paper used a GHRH-receptor-targeted botulinum-neurotoxin construct to further characterise pulsatile-secretion mechanisms (PMID 23825127). Combined GHRH + GHRP research can examine how dual-receptor stimulation modulates the pulsatile-release profile compared with single-class stimulation.

Postoperative ileus and gastric-motility research forms a stream specific to Ipamorelin. The 2014 Beck Phase 2 randomised controlled trial published in the International Journal of Colorectal Disease provides the clinical-research-stage data point (PMID 25331030). This stream is not directly relevant to CJC-1295 but contextualises Ipamorelin's broader pharmacology profile.

Comparative GHRH-analogue research positions CJC-1295 within the broader development-era class. The 2010 Falutz Tesamorelin paper provides comparative clinical-research data for HIV-associated lipodystrophy (PMID 20554713). Sermorelin is the unmodified hGHRH(1-29) parent peptide; CJC-1295 No DAC's four-substitution modifications enhance plasma stability without compromising receptor agonism. The 2013 Sattler review compiled GH-axis-and-aging research framings under which both blend components appear (PMID 24054930).

Translation to human clinical application has been limited for both compounds. CJC-1295 with DAC progressed through Phase 2 trials but did not advance to a marketed therapeutic. Ipamorelin progressed through Phase 2 in the postoperative-ileus indication and similarly did not advance. Multiple groups have studied, characterised, and observed both compounds across in vitro, animal-model, and clinical-research contexts — the combined-compound translation is not yet documented in clinical-trial-stage publications.

The blend contains two distinct compounds at the proportions listed below.

Total peptide loading per vial: 10 mg. Form: lyophilized white-to-off-white powder. Solubility: bacteriostatic water; sterile water for injection. Storage: lyophilized in a 10 mL intranasal-spray bottle; reconstituted with the included 0.3% potassium sorbate solution. Purity: ≥99% per component by HPLC, verified per batch by Janoshik Analytical against the two expected molecular masses.

Per-batch COA documentation reports the analytical results for each component compound separately. Investigators integrating the blend into mass-spec-coupled protocols should expect two distinct mass-spec peaks corresponding to the two components.

Unopened lyophilized vials hold up well under dry ambient storage; usable activity persists for several weeks even without refrigeration. The recommended container is the unopened original vial — keep the seal intact until reconstitution. Refrigeration at 2–8 °C is appropriate once the working timeline extends past a month. A standard freezer at −20 °C handles archival storage.

Keep vials shielded from light, ideally in their original outer packaging. Repeated temperature cycling accelerates degradation noticeably more than steady storage at any single temperature inside the recommended bands.

After reconstitution, refrigerate the solution at 2–8 °C without delay. The typical working window is four to six weeks at fridge temperature. Past that window, peptide concentration drifts downward through chemical degradation pathways. The 0.9% benzyl alcohol in bacteriostatic water holds back bacterial contamination but does not arrest hydrolysis, oxidation, and aggregation processes accumulating in any aqueous peptide solution. The two components may degrade at slightly different rates; the per-component COA mass-spec data is the only direct status confirmation.

When a research timeline extends past six weeks, common practice is splitting the reconstituted solution into single-use volumes and freezing them at −20 °C immediately. Thaw individual aliquots overnight in a refrigerator — never at room temperature.

The reconstituted product should be visually transparent and colourless with no suspended particulate. Discard any vial showing turbidity, suspended particulate, yellowing, or visible precipitate. The diluent of choice is USP-grade bacteriostatic water containing 0.9% benzyl alcohol.

The CJC-1295 + Ipamorelin Blend pairs Ronin's two GH-axis compounds in a single vial at half the per-component standalone loading. Researchers focused on a single mechanism class use the standalone vials; researchers studying dual-receptor (GHRH + GHRP) protocols often use the blend format for convenient pre-mixed ratios. Tesamorelin is an alternative GHRH analogue with different stabilisation chemistry, available as a standalone for comparative work.

This nasal spray ships unreconstituted. The peptide is supplied lyophilized in a 10 mL intranasal-spray bottle together with the 0.3% potassium sorbate solution required to reconstitute it (included) — potassium sorbate acts as a preservative suited to an intranasal solution. Add the full 10 mL of the included solution to reconstitute; the resulting concentration is the bottle’s peptide load divided by 10 mL. A typical metered intranasal actuation delivers approximately 0.1 mL, so each spray delivers roughly one-hundredth of the total peptide load.

1. Bring the spray bottle and the included 0.3% potassium sorbate solution to room temperature.
2. Sanitise the stoppers with an alcohol swab.
3. Add the full 10 mL of the included 0.3% potassium sorbate solution to the lyophilized peptide, directing the liquid against the inner wall — never onto the lyophilized cake.
4. Invert slowly or swirl gently until dissolved. Do not vortex or shake.
5. Attach the spray pump to the bottle and prime it before first use.
6. Store the reconstituted solution refrigerated at 2–8 °C and avoid repeated freeze–thaw cycles.

1. Thorner MO. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion. Recent Prog Horm Res. 1997;52:215-244. PMID: 9238854
2. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822 | doi:10.1530/eje.0.1390552
3. Johansen PB et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues. Xenobiotica. 1998;28(11):1083-1092. PMID: 9879640 | doi:10.1080/004982598238976
4. Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary. Endocrinology. 2005;146(7):3052-3058. PMID: 15817669 | doi:10.1210/en.2004-1286
5. Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683 | doi:10.1210/jc.2005-1536
6. Alba M et al. Once-daily administration of CJC-1295. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1297. PMID: 16822960 | doi:10.1152/ajpendo.00201.2006
7. Ionescu M et al. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 17018654 | doi:10.1210/jc.2006-1702
8. Falutz J et al. Effects of tesamorelin (TH9507), a GHRH analog, in HIV-infected patients. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PMID: 20554713 | doi:10.1210/jc.2010-0490
9. Leggett J et al. GHRH receptor-targeted botulinum neurotoxin selectively inhibits pulsatile GH secretion. Endocrinology. 2013;154(9):3305-3318. PMID: 23825127 | doi:10.1210/en.2012-2175
10. Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. 2013;27(4):541-555. PMID: 24054930 | doi:10.1016/j.beem.2013.05.003
11. Beck DE et al. Phase 2 randomized controlled trial of ipamorelin for postoperative ileus. Int J Colorectal Dis. 2014;29(12):1527-1534. PMID: 25331030 | doi:10.1007/s00384-014-2030-8
12. Ferro P et al. Structure-activity relationship for peptidic growth hormone secretagogues. Drug Test Anal. 2017;9(3):432-437. PMID: 26811125 | doi:10.1002/dta.1947